$1.69 Billion is the total value of Sofinnova Investments, Inc.'s 53 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NGM | Exit | NGM Biopharmaceuticals Inccall | $0 | – | -150,000 | -100.0% | -0.11% | – |
| INSM | Exit | Insmed Inc | $0 | – | -220,665 | -100.0% | -0.28% | – |
| ARQT | Exit | Arcutis Biotherapeutics Inc | $0 | – | -274,330 | -100.0% | -0.30% | – |
| RGNX | Exit | Regenxbio Inc | $0 | – | -213,959 | -100.0% | -0.33% | – |
| INBX | Exit | Inhibrx Incput | $0 | – | -350,000 | -100.0% | -0.37% | – |
| ACET | Exit | Adicet Bio Inc | $0 | – | -491,965 | -100.0% | -0.41% | – |
| AKUS | Exit | Akouos Inc | $0 | – | -1,515,074 | -100.0% | -0.60% | – |
| EW | Exit | Edwards Lifesciences Corp | $0 | – | -147,200 | -100.0% | -0.71% | – |
| LLY | Exit | Lilly Eli & Co | $0 | – | -45,500 | -100.0% | -0.86% | – |
| IRTC | Exit | iRhythm Technologies Inc | $0 | – | -140,095 | -100.0% | -1.02% | – |
| ISRG | Exit | Intuitive Surgical Inc | $0 | – | -96,300 | -100.0% | -1.05% | – |
| MRK | Exit | Merck & Co Inccall | $0 | – | -300,000 | -100.0% | -1.50% | – |
| GILD | Exit | Gilead Sciences Inc | $0 | – | -482,400 | -100.0% | -1.73% | – |
| IWM | Exit | iShares Russell 2000 ETFput | $0 | – | -200,000 | -100.0% | -1.92% | – |
| XLV | Exit | Health Care Select Sector SPDRput | $0 | – | -300,000 | -100.0% | -2.11% | – |
| QQQ | Exit | Invesco QQQ Trust Series 1put | $0 | – | -150,000 | -100.0% | -2.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.